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ABSTRACT
The global health effort to eradicate
poliomyelitis (polio) has encountered a
number of unforeseen and unpredictable
challenges. This article provides a timely
review of progress made toward eradication,
including the polio vaccines in use, and
explores the reasons for delays in eradication
target dates. It provides an overview of some of
the remaining barriers to eradication and looks
toward overcoming these through the Polio
Eradication and Endgame Strategic Plan.
Keywords: Polio; Polio eradication; Polio
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INTRODUCTION
The global health effort to eradicate
poliomyelitis (polio) has encountered a
number of unforeseen and unpredictable
challenges which have been well documented
[1]. This article provides a timely review of these
challenges and looks toward overcoming the
remaining barriers to eradication.
METHODS
The authors undertook a comprehensive
literature review using the Internet and the
databases JSTOR, PubMed, ScienceDirect and
SwetsWise. The following search terms were
used: ‘‘polio’’, ‘‘poliomyelitis’’, ‘‘polio
eradication’’, ‘‘polio endgame’’, ‘‘polio vaccine’’
and ‘‘poliovirus’’.
DISCUSSION
Polio is a highly infectious viral disease, which
can cause paralysis and, in some cases, death.
Wild polioviruses are those that occur naturally.
There are three serotypes of wild poliovirus:
type-1, type-2, and type-3. The poliovirus enters
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the body through the mouth, multiplies in the
oropharynx and the small intestine and exits in
the feces from which it can spread rapidly
through a community, especially in areas with
poor hygiene and sanitation. The virus invades
the local lymphoid tissues in the
gastrointestinal tract, and may then enter the
bloodstream and spread to the central nervous
system. The virus may also spread to the central
nervous system along the peripheral nerves.
Over 90% of people infected with poliovirus
have either no or very mild symptoms, which
can easily go unrecognized [2]. This makes it
very difficult to identify an outbreak
immediately as asymptomatic infections can
spread the infection ‘silently’ to others before
the first case of polio paralysis is detected.
Therefore, herd immunity must be attained to
prevent transmission and outbreaks of polio
occurring.
Before the twentieth century, poor hygiene
and sanitation meant that almost all children
were exposed to poliovirus during infancy,
which enabled natural immunity to build up
in populations. The industrial revolution
brought great sanitary improvements,
including the separation of sewage from
drinking water. While this proved vital in
increasing public health standards in general,
it initially had disastrous effects in relation to
polio cases. It reduced childhood exposure to
the virus and lowered immunity levels in
communities, creating the perfect setting for
epidemics to ignite [3].
By the late 1980s, polio had been eliminated
from most industrialized countries by routine
immunization programs. However, it was
estimated that polio still paralyzed more than
1,000 children every day globally, and that the
poliovirus was circulating in more than 125
lesser developed countries [4]. Building on the
global health success of the eradication of
smallpox, and encouraged by the progress
made toward interrupting wild poliovirus
transmission in the Americas in the early
1980s, in 1988 the World Health Assembly
declared the commitment of the World Health
Organization (WHO) to the global eradication
of poliomyelitis by the year 2000 [5]. The Global
Polio Eradication Initiative (GPEI) was formed
to achieve this target, led by WHO, the United
Nations Children’s Fund, Rotary International,
and the United States Centers for Disease
Control and Prevention [6].
The GPEI understood that increasing
population immunity by routine vaccination
supplemented by national mass immunization
campaigns, and enhancing the epidemiological
surveillance of the disease so that outbreaks
could be rapidly detected and contained, would
be the key to interrupting the transmission of
wild poliovirus and achieving eradication [6].
The vaccine most used globally is the
trivalent oral polio vaccine (tOPV or ‘Sabin
vaccine’), which is effective against all three
types of wild poliovirus. Use of tOPV can result
in the ‘passive’ immunization of people living
in areas of poor hygiene and sanitation who
have not been directly vaccinated, as the virus
continues to be excreted through the feces into
the environment for several weeks after
vaccination. A further advantage to its use is
its cost, estimated to be between 11 and 14 US
cents per dose [7].
There are also two more oral polio vaccines
in use today: the monovalent vaccine (mOPV)
and the bivalent vaccine (bOPV). In children
being immunized for the first time, the
monovalent vaccine (mOPV), consisting of
just one type of the live attenuated strains of
poliovirus, provides a greater immunity to the
specific type of poliovirus being targeted and
also provides increased immunity for the same
number of doses compared with tOPV. This
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may be because there is no competition from
the other two virus types in the vaccine [8]. The
bivalent vaccine (bOPV) consists of live
attenuated strains of both type-1 and type-3
poliovirus and improves the efficiency and
impact of vaccination campaigns in areas
where both types of poliovirus co-circulate. It
is more effective than tOPV and almost as
effective as mOPV in achieving protection [9].
Unfortunately, in very rare cases,
(approximately 1 in every 2.7 million first
doses of the vaccine), the oral polio vaccines
can cause a condition known as vaccine-
associated paralytic polio [7]. Even more
concerning is the potential for the live
attenuated strains of the vaccine viruses to
revert and re-acquire neurovirulence, resulting
in circulating vaccine-derived polioviruses
(cVDPVs) [10]. cVDPVs could pose a threat in
a post-eradication world, with the ability to
cause devastating outbreaks of polio at a time
when immunity levels are reduced.
In most high-income countries, where the
risk of polio infection is low, the inactivated
polio vaccine (IPV or ‘Salk vaccine’) is used. IPV
consists of ‘‘killed’’ strains of all three
polioviruses, which is delivered via an
injection. As it is not a ‘‘live’’ vaccine, IPV
poses no risk to the recipient of vaccine-
associated paralytic polio, nor is there any
possibility of cVDPVs emerging [11]. However,
it does need to be administered by a trained
health worker, induces very low levels of
immunity in the intestine and is over five
times more expensive than the oral polio
vaccine [11].
Following its launch in 1988, the GPEI had a
promising start and the Americas was the first
WHO Region to be certified polio-free of all
three types of wild poliovirus in 1994. By the
year 2000, the global incidence of polio had
been reduced by over 99% [12] and every
endemic country had implemented some form
of polio-eradication strategy. Much effort had
been made to attain herd immunity by
supplementing the preceeding level of polio
vaccination coverage in routine immunization
programs with compaings [13].
However, delays in the global
implementation of eradication strategies, in
part due to lack of political commitment,
funding and competing development and
health priorities meant that the initial target
for eradication by the year 2000 was missed.
Nevertheless, progress continued with the
certification of two more WHO Regions as
polio-free: the Western Pacific Region in 2000
[14] and the European Region in 2002 [15].
In 2003, only six polio-endemic countries
remained: Afghanistan, Egypt, India, Niger,
Nigeria and Pakistan. Although Egypt and
Niger were later declared polio-free by 2005,
the remaining four countries faced various
challenges to the eradication effort over the
next 10 years. Following the elimination of
type-2 wild poliovirus from human
populations in 1999 when the last infection
was identified in India [16], and because tOPV
provides less optimum protection against
poliovirus serotypes 1 and 3 in some tropical
settings, the monovalent and bivalent
formulations of the vaccine were introduced
to more closely target and rapidly interrupt the
remaining virus types in circulation,
particularly in densely populated areas of high
intensity of transmission [17].
India’s greatest challenge to eradication was
the sub-optimal effectiveness of tOPV in areas of
high birth rates, poor sanitation as well as dense
and migratory communities. This was
particularly apparent in northern India and
was only overcome by a substantial effort to
push coverage rates to over 95% in particularly
vulnerable populations and areas, and the
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careful and tactical use of mOPV and bOPV [1].
India was finally removed from the WHO list of
polio-endemic countries in early 2012; an
enormous achievement, considering that in
2009, India had the highest number of polio
cases in the world [18]. It is expected that India
will be officially certified as polio-free in 2014
[19].
The nature of poliovirus has posed its own
challenge to eradication. Every child needs to be
vaccinated multiple times to ensure full
immunity, depending on the vaccine used
[20]. This provides a significant logistical
challenge to vaccinators, especially with
migratory, displaced or hard to access
populations. It can be very difficult to
ascertain when and how many doses of
vaccine each child has received and how many
children were missed on vaccination days [1].
This can pose a high risk to immunity levels as
the virus may be transmitted over large
distances with little warning.
Natural disasters such as floods, earthquakes,
hurricanes and tsunamis can also contribute to
delays in eradication efforts. These can all have
a detrimental impact on communications and
road and health infrastructures, in some cases
making it impossible to reach people except by
air. Hospitals, medical centers and cold chain
storage facilities can be damaged or destroyed
and local health workers displaced.
The re-importation of wild poliovirus to
countries that were previously polio-free has
also complicated efforts. Angola, Chad and the
Democratic Republic of Congo have all
experienced re-established transmission,
resulting in reservoirs from where neighboring
countries have been repeatedly infected. In
addition, the transmission of cVDPVs has also
caused problems in a number of countries. Poor
management and oversight of polio and routine
immunization campaigns continue to be a
major risk factor for outbreaks following re-
importation of the poliovirus into previously
polio-free countries [1]. Gaps in the quality of
acute flaccid paralysis surveillance have also
compromised the speed of outbreak response
activities.
Only three polio-endemic countries remain
in 2013: Afghanistan, Nigeria and Pakistan. It
can be argued that geopolitical events in all
three countries, such as war and insecurity, in
addition to the loss of community confidence
in the immunization program in some areas of
these countries, have continued to hamper
eradication progress. Civil disturbance
displaces children and can result in the
blocking of access routes during vaccination
campaigns. Deep distrust of perceived Western-
led initiatives has also impacted on polio
immunization efforts. False rumors, such as
those that circulated in Nigeria in 2003 that
the polio vaccine was being used to sterilize
Muslim girls [21] and those that circulated in
Pakistan in 2011 that the USA and its allies were
running spying networks through vaccination
campaigns [22] have contributed to a loss of
community confidence in the immunization
program. A series of fatal attacks in December
2012 and February 2013 targeting polio
vaccination workers in Pakistan and Nigeria,
respectively, has led to fear and confusion
around vaccination campaigns and appears to
have compromised the vaccine coverage in
some areas. This continues to affect
immunization uptake and intensive efforts
have been made to engage local community
and religious leaders to champion the cause.
The combination of missed targets for
eradication and the high costs of
implementing the GPEI’s activities worldwide
has prompted some public health officials to
question the concept of eradication in favor of a
strategy of ‘‘effective control’’. They argue that
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maintaining less than 500 polio cases per year
would be cheaper than completing eradication
[23]. This suggestion has so far been rejected by
the international public health and donor
communities, and continued polio
surveillance still requires extensive financial
and operational efforts. Epidemiological
modeling has suggested that in low-income
countries alone, a switch to ‘control’ would
result in an estimated 4 million polio-paralyzed
children over the next 20 years [24].
Furthermore, a 2010 study based on GPEI
activities from 1988 through 2035 estimated
that the elimination of wild poliovirus by 2015
would produce net profits of around US $50
billion from reduced treatment costs and gains
in economic productivity by preventing polio-
related disability, with low-income countries
accounting for approximately 85% of the net
benefits [25].
The gains from the global implementation of
polio eradication initiatives are not only
monetary. The GPEI has trained an enormous
cadre of staff who understand basic health care
needs and can provide services to people in the
poorest areas in the world. Activities
undertaken under the auspices of the GPEI
have also contributed to the improvement of
public health at large and increased the
effectiveness of other preventive programs.
Polio program staff have supported the
surveillance of and response to measles,
tetanus, meningitis, yellow fever and cholera.
Furthermore, in many countries, the GPEI
successfully expanded its delivery model to
include the distribution of Vitamin A
supplements alongside polio immunizations,
estimated to have averted at least 1.1 million
Vitamin A deficiency-related deaths from 1988
to 2010 [25].
In 2012, the World Health Assembly
requested a comprehensive polio endgame
strategy [26], which culminated in the
development of the Polio Eradication and
Endgame Strategic Plan 2013–2018 [27]. The
Plan is based on broad consultations with
national health authorities, global health
initiatives, scientific experts, donor partners
and other stakeholders. The Plan has four
main objectives: to stop all wild poliovirus
transmission by the end of 2014 and new
cVDPV outbreaks within 120 days of
confirmation of the first case; to strengthen
immunization systems, introduce IPV into the
routine immunization schedule globally and
withdraw the use of oral polio vaccines; certify
all regions of the world polio-free by 2018 and
ensure the safe containment of all poliovirus
stocks; and to ensure that the world remains
permanently polio-free with careful legacy
planning as well as planning for the transition
of assets and the infrastructure of the polio
program to benefit other development goals
and global health interventions.
The Plan aims to withdraw the use of the
type-2 component of OPV in all routine
immunization programs by mid-2016. The
importance of withdrawing the type-2
component as quickly as possible was
reinforced by the 2012 polio outbreaks caused
by circulating type-2 vaccine-derived
polioviruses, which left 65 children paralyzed
in 7 countries: Afghanistan, Chad, the
Democratic Republic of Congo, Kenya, Nigeria,
Pakistan and Somalia [28]. As of August 13,
2013, 17 cases of polio due to circulating type-2
vaccine-derived polioviruses were reported in 6
countries: Afghanistan, Cameroon, Chad,
Nigeria, Pakistan and Somalia [29].
The withdrawal of the type-2 component of
OPV will require the strengthening of
immunization systems, the introduction of at
least one dose of affordable IPV into the routine
immunization schedule globally and then the
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replacement of tOPV with bOPV. This would
pave the way for the eventual withdrawal of
bOPV use in 2019–2020.
The GPEI is currently undertaking research
to find ways of enabling low-income countries
to access low-cost IPV options, instead of
relying on costly imports. A multi-pronged
research agenda is being pursued to
investigate: a dose-reduction strategy using
intradermal administration of fractional IPV
doses; a schedule requiring fewer doses;
adjuvant use to reduce the quantity of antigen
required in the vaccine; and IPV production
processes to facilitate manufacture in low-cost
sites. The GPEI is also investigating the mucosal
immune responses stimulated by IPV compared
with those stimulated by OPV. In addition,
work is being carried out to develop an IPV
based on ‘Sabin’ attenuated virus seed-strains
[30]. While traditional manufacturing of IPV
involves large amounts of infectious ‘Salk’ seed
strains, IPV containing the attenuated Sabin
seed strains would reduce the severity of
potential consequences in the event of a
biocontainment failure at an IPV
manufacturing facility.
Financing of the eradication effort remains a
huge challenge. In the first quarter of 2012,
GPEI activities were scaled down in 24 high-risk
countries because of an acute funding shortage
[31]. The budget for the Plan is US $5.5 billion,
with a peak spending in 2013, then estimated to
decline annually [32]. As of June 1, 2013, the
GPEI was tracking over US$ 217 million in firm
prospects, which if fully operationalized could
close the 2013 funding gap, provided enough
unspecified funds are secured to cover all cost
categories [32]. However, pledges are very
different to signed agreements and cash
disbursements, and there is still a US $1.5
billion funding gap to fully resource the Plan.
This shortfall has the potential to hamper the
goal of eradication.
Today, eradication efforts continue. In 2012,
223 wild poliovirus cases were reported globally,
more than a 60% decline compared with 2011
and only 5 countries reported cases in 2012
compared with 16 in 2011 [33]. As of August 13,
2013, 181 wild poliovirus cases had already
been reported [33].
CONCLUSION
The global health effort to eradicate polio has
faced numerous challenges since the launch of
the GPEI. It is hoped that the last remaining
obstacles have been identified and will be
overcome within the established timeframe of
the Polio Eradication and Endgame Strategic
Plan. Crucially, success in the polio endgame
would provide a strong evidence base and
encourage political commitment to other such
eradication initiatives. However, building on
the lessons learned from the polio experience,
any eventual strategy for measles eradication
should strengthen routine immunization and
not merely become a substitute [34].
ACKNOWLEDGMENTS
No funding or sponsorship was received for this
study or publication of this article. Ms Lien is
the guarantor for this article, and takes
responsibility for the integrity of the work as a
whole.
Conflict of interest. Gemma Lien and David
L. Heymann declare no conflicts of interest.
Open Access. This article is distributed
under the terms of the Creative Commons
Attribution Noncommercial License which
172 Infect Dis Ther (2013) 2:167–174
123
permits any noncommercial use, distribution,
and reproduction in any medium, provided the
original author(s) and the source are credited.
REFERENCES
1. Aylward B, Tangermann R. The global polio
eradication initiative: lessons learned and
prospects for success. Vaccine. 2011;29:D80–5.
2. Polio and Prevention, Global Polio Eradication
Initiative 2013. http://www.polioeradication.org/
Polioandprevention.aspx. Accessed 19 August 2013.
3. Bunimovich-Mendrazitsky S, Stone L. Modeling
polio as a disease of development. J Theor Biol.
2005;237:302–15.
4. History of Polio, Global Polio Eradication Initiative
2013. http://www.polioeradication.org/Polioand
prevention/Historyofpolio.aspx. Accessed 30 August
2013.
5. Resolution No. WHA41.28: Global eradication of
poliomyelitis by the year 2000. Forty-first World
Health Assembly. World Health Organization 1988.
http://www.who.int/ihr/polioresolution4128en.pdf.
Accessed 19 August 2013.
6. About Us, Global Polio Eradication Initiative 2013.
http://www.polioeradication.org/AboutUs.aspx. Acces-
sed 30 August 2013.
7. Oral polio vaccine (OPV), Global Polio Eradication
Initiative 2013. http://www.polioeradication.org/
Polioandprevention/Thevaccines/Oralpoliovaccine
OPV.aspx. Accessed 19 August 2013.
8. Grassly N, Wenger J, Durrani S, Bahl S, Deshpande
J, Sutter R, et al. Protective efficacy of a monovalent
oral type 1 poliovirus vaccine: a case–control study.
Lancet. 2007;369:1356–62.
9. Sutter R, John T, Jain H, Agarkhedkar S, Ramanan P,
Verma H, et al. Immunogenicity of bivalent types 1
and 3 oral poliovirus vaccine: a randomized,
double-blind, controlled trial. Lancet.
2010;376:1682–8.
10. Heymann D, Sutter R, Aylward B. A vision of a
world without polio: the OPV cessation strategy.
Biologicals. 2006;34:75–9.
11. Inactivated polio vaccine (IPV), Global Polio Eradi-
cation Initiative 2013. http://www.polioeradication.
org/Polioandprevention/Thevaccines/Inactivated
poliovaccine(IPV).aspx. Accessed 30 August 2013.
12. Report of the Independent Monitoring Board of the
Global Polio Eradication Initiative, April 2011. http://
www.polioeradication.org/Portals/0/Document/
Data&Monitoring/IMB_Reports/IMB_Report_April
2011.pdf. Accessed 19 August 2013.
13. Aylward B, Acharya A, England S, Agocs M, Linkins
J. Global health goals: lessons from the worldwide
effort to eradicate poliomyelitis. Lancet.
2003;362:909–14.
14. Executive Board document EB107/28. Eradication
of poliomyelitis: Report by the Secretariat. World
Health Organization 2000. http://apps.who.int/gb/
archive/pdf_files/EB107/ee28.pdf. Accessed 19
August 2013.
15. Executive Board document EB111/32. Eradication
of poliomyelitis: Report by the Secretariat. World
Health Organization 2002. http://apps.who.int/gb/
archive/pdf_files/EB111/eeb11132.pdf. Accessed 19
August 2013.
16. Transmission of wild poliovirus type 2: apparent
global interruption. Wkly Epidemiol Record.
2001;76(13):95–97.
17. Grassly N, Fraser C, Wenger J, Deshpande J, Sutter
R, Heymann D, et al. New strategies for the
elimination of polio from India. Science.
2006;314:1150–3.
18. Global Polio Eradication Initiative Annual Report
2009, World Health Organization 2010. http://
www.polioeradication.org/content/publications/
AnnualReport2009_ENG.pdf. Accessed 19 August
2013.
19. John T, Vashishtha V. Eradicating poliomyelitis:
India’s journey from hyperendemic to polio-free
status. Indian J Med Res. 2013;137(5):881–94.
20. The Vaccines, Global Polio Eradication Initiative
2013. http://www.polioeradication.org/Polioand
prevention/Thevaccines.aspx. Accessed 30 August
2013.
21. Yahya M. Polio vaccines—difficult to swallow. The
story of a controversy in northern Nigeria. Institute
of Development Studies. 2006; Working Paper 261.
http://www.ids.ac.uk/files/Wp261.pdf. Accessed 19
August 2013.
22. Boone J. Taliban leader bans polio vaccinations in
protest at drone strikes. The Guardian, 26 June
2012. http://www.guardian.co.uk/world/2012/jun/
26/taliban-bans-polio-vaccinations. Accessed 19
August 2013.
23. The Case for Completing Polio Eradication, World
Health Organization 2007. http://www.who.int/
Infect Dis Ther (2013) 2:167–174 173
123
immunization/sage/TheCase_FINAL.pdf. Accessed
19 August 2013.
24. Thompson K, Duintjer Tebbens R. Eradication
versus control for poliomyelitis: an economic
analysis. Lancet. 2007;369 (9570):1363–71.
25. Duintjer Tebbens R, Pallansch M, Cochi S, Wassilak
S, Linkins J, Sutter R, et al. Economic analysis of the
global polio eradication initiative. Vaccine.
2011;29(2):334–43.
26. Resolution No. WHA65.5: Poliomyelitis:
intensification of the global eradication initiative.
Sixty-fifth World Health Assembly. World Health
Organization 2012. http://apps.who.int/gb/ebwha/
pdf_files/WHA65/A65_R5-en.pdf. Accessed 19
August 2013.
27. Polio Eradication and Endgame Strategic Plan
2013–2018: Executive Summary. Global Polio
Eradication Initiative 2013. http://www.
polioeradication.org/Portals/0/Document/
Resources/StrategyWork/PEESP_ES_EN_A4.pdf.
Accessed 19 August 2013.
28. Poliomyelitis: intensification of the global
eradication initiative, report by the Secretariat.
Sixty-sixth World Health Assembly, document
A66/18. World Health Organization 2013. http://
apps.who.int/gb/ebwha/pdf_files/WHA66/A66_18-
en.pdf. Accessed 19 August 2013.
29. Circulating vaccine-derived poliovirus (cVDPV)
2000–2013 (data as of 13 August 2013), Global
Polio Eradication Initiative 2013. http://www.
polioeradication.org/Dataandmonitoring/Polio
thisweek/Circulatingvaccinederivedpoliovirus.aspx.
Accessed 19 August 2013.
30. Polio vaccine technology transfer continues, 20
March 2013, Global Polio Eradication Initiative.
http://www.polioeradication.org/Mediaroom/News
stories/Newsstories2013/tabid/488/iid/286/Default.
aspx. Accessed 19 August 2013.
31. Global Polio Eradication Initiative Annual Report
2011, World Health Organization 2012. http://
www.polioeradication.org/Portals/0/Document/
AnnualReport/AR2011/GPEI_AR2011_A4_EN.pdf.
Accessed 19 August 2013.
32. Financial Resource Requirements 2013–2018: as of 1
June 2013, World Health Organization 2013. http://
www.polioeradication.org/Portals/0/Document/
Financing/FRR_EN_A4.pdf. Accessed 19 August
2013.
33. Polio this week—as of 13 August 2013, Global
Polio Eradication Initiative, 2013. http://www.
polioeradication.org/Dataandmonitoring/Poliothis
week.aspx. Accessed 19 August 2013.
34. Heymann D, Fine P, Griffiths U, Hall A, Mounier-
Jack S. Measles eradication: past is prologue. Lancet.
2010;376:1719.
174 Infect Dis Ther (2013) 2:167–174
123
